Hims & Hers Health, Inc. (HIMS)
Hims & Hers: It's Time To Get Aggressive
Hims & Hers is a Strong Buy, as shares appear historically cheap due to temporary margin compression and regulatory concerns. HIMS's recurring revenue model, 70%+ gross margins, and rapid subscriber growth underpin a compelling long-term growth thesis despite recent profit volatility. Significant investments in global expansion, new product lines, and vertical integration are expected to drive future margin expansion and revenue acceleration.
Hims & Hers Health, Inc. (HIMS) Stock Declines While Market Improves: Some Information for Investors
Hims & Hers Health, Inc. (HIMS) reached $29.68 at the closing of the latest trading day, reflecting a -1.98% change compared to its last close.
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hims & Hers Scales Platform-Led Digital Healthcare Access and Care
HIMS expands its tech-driven care platform with new diagnostics, AI tools and specialty treatments for personalized health.
Hims & Hers Health: The Reset Nobody Expected
Revenue grew nearly 50% year over year in Q3 2025 to ~$600 million, with ARPU rising and free cash flow reaching $79 million. Gross margin declined to ~74% from high-70s levels due to GLP-1 shipping cadence changes, price cuts, and facility expansion inefficiencies. Operating cash flow approached $150 million in the quarter, with over $1 billion in cash and investments supporting reinvestment and buybacks.
HIMS vs. TEM: Which Health-Tech Stock Looks More Compelling?
Hims & Hers and Tempus AI are transforming digital health in distinct ways, but which platform looks more compelling right now? Let's dive in.
Hims & Hers Expands Platform-Led Access to Digital Healthcare
HIMS leverages a software-driven platform to scale personalized digital care across new health categories and markets.
Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now?
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Hims & Hers Health, Inc. (HIMS) Outpaced the Stock Market Today
In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $32.34, indicating a +2.05% shift from the previous trading day.
Hims & Hers Expands Platform-Led Access to Provider-Directed Care
HIMS broadens access to provider-led care with new offerings in diagnostics, hormonal health and at-home testing.
Hims & Hers Health: Capitalizing On Healthcare Innovation
Hims & Hers Health remains a speculative buy for aggressive growth investors, driven by its pivot toward precision medicine and AI-enabled healthcare. Recent volatility stems from regulatory risks, the Novo Nordisk partnership breakup, and shifting GLP-1 compounding regulations impacting revenue and investor sentiment. HIMS's valuation sits between telehealth and AI/genomics peers, with substantial upside if it becomes more like AI/genomics companies but significant downside if risks materialize.
Hims & Hers Growth Story Has A Lot To Prove In 2026
Hims & Hers is down 50% from all-time highs amid fading momentum in their compounded GLP-1 offerings, while new growth vectors are yet to translate into revenue acceleration. Sequential revenue deceleration, margin contraction, and lowered FY25 guidance have pressured Hims stock, but management maintains ambitious 2030 targets. New growth vectors—testosterone, menopause, Labs, and international expansion are promising, yet have not driven meaningful revenue acceleration.
